Premature ejaculation is a type of male sexual disorder with an intravaginal ejaculatory latency time of less than one minute. High levels of sexual anxiety and altered sensitivity of serotonin receptors are found as an evidence in most of the men with premature ejaculation. Premature ejaculation can be defined by three criteria such as lack of sexual satisfaction, short ejaculatory latency, and lack of control over ejaculation. Some of the risk factors associated with premature ejaculation are endocrinopathy, opiate withdrawal, chronic prostatitis, and alcohol abuse. CTC Bio, Inc. is in the process of developing CDFR0812 as an adrenergic uptake inhibitor for the treatment of premature ejaculation. Ixchelsis Limited is in the process of developing IX-01 as an oxytocin receptor antagonist for the treatment of premature ejaculation. Some of the companies and universities having the pipeline of premature ejaculation include CTC Bio, Inc., Allergan plc, Ixchelsis Limited, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.